ERBB2 and breast cancer: With the goal of discovering RNA-fusions that can be targeted for neoantigen peptide candidates, we performed RNA-Sequencing of triple negative (TNBC), HER2+ and hormone receptor positive (HR+) breast cancer samples (n=25 each).